Intervention: Liothyronine Sodium
Trial phase: Phase 1
ATC code: H03AA02
SMILES: NC(Cc1cc(I)c(Oc2ccc(O)c(I)c2)c(I)c1)C(=O)[O-].[Na+]
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 10
Group description: Subjects will be divided into 4 groups. The first group will take 25 mcg twice daily for one week. The second group will take 37.5 mcg twice daily for one week. The third group will take 50 mcg twice daily for one week. The firth group will take 75 mcg twice daily for one week

Liothyronine sodium: Subjects will be divided into 4 groups of progressively escalating doses. Each group will have 6 subjects 4 will receive the active treatment and 2 will receive the placebo. The first group will receive 25 mcg twice daily for one week. The second group will receive 37.5 mcg twice daily for one week. The third group will receive 50 mcg twice daily for one week. The forth group will receive 75 mcg twice daily for one week.
Eligibility criteria:
Inclusion Criteria:

Confirmed diagnosis of MS of any type
Age 18 to 50 years
Weight range 45-90 kg (100-200 lbs)
Lesions on brain MRI

Exclusion Criteria:

History of hypo or hyperthyroidism and a normal TSH
History of high blood pressure (hypertension) [
Resting blood pressure greater than 150/95, resting heart rate greater than 100
History of coronary artery disease or clinically significant arrhythmia, clinically significant abnormalities on EKG
History of diabetes
History of anemia or renal (kidney) disease
Clinically significant abnormalities on metabolic panel or serum hematocrit below 32 %
History of atrophic gastritis
History of anxiety disorder or bipolar disorder
Serious psychiatric or medical conditions that would preclude reliable participation in the study
Use of illicit substances or alcohol abuse
Current use of fingolimod (Gilenya)
Current or prior use of mitoxantrone (Novantrone)
Current use of stimulants (methylphenidate, atomoxetine, dextroamphetamine,phentermine)
Current use of any blood thinners such as warfarin or apixaban (Aspirin is ok)
Medications which would metabolized faster in the presence of thyroid hormone (Insulin, oral hypoglycemic agents and oral anticoagulants)
Severe head tremors (which would impair the ability to perform VEPs)
Present or recent use of medications that could interact with the thyroid hormone (iodine containing agents such as kelp supplements, amiodarone, iodinated contrast given for CT or xray), P450 stimulants (phenytoin, carbamazepine, phenobarbital, and rifampin)
Corrected visual acuity worse than 20/50 in either eye or other eye issues that would prevent reading of a standard eye chart
Head tremors or other tremors that would prevent sitting relatively still for a vision test
Patients taking proton pump inhibitors (PPIs) or H2 blockers will be excluded unless they can safely not take these medications during the week of study drug administration.
Patients taking Ampyra (dalfampridine) will be excluded unless they can safely not take these medications during the week of study drug administration.
Pregnancy, breastfeeding, or intention to become pregnant in the following month
Inability to receive an MRI (e.g. implanted metal device)